A.I. Burnasyan FMBC clinical bulletin. 2022 № 3
A.A. Zavyalov1, D.A. Andreev2, S.E. Varlamova1
Clinical trials of metastatic non-small cell lung cancer therapy show promising results: ASCO Congress 2022
1A.I. Burnasyan Federal Medical Biophysical Center, Moscow, Russia
2The State Budgetary Institution Research Institute for Healthcare Organization and Medical Management
of Moscow Health Department. Moscow, Russian Federation
Contact person: Bodrov Anton Vladimirovich: Bodroff.Antoha@yandex.ru
Abstract
Lung cancer (LC) is a commonly diagnosed malignant tumor that annually claims the lives of about 1.8 million peoples. In the Russian Federation, the group of tumors of the respiratory organs: trachea, bronchi and lung occupies the third place (9.4%, both sexes) in the structure of oncological morbidity after malignant neoplasms of the skin with melanoma (15.0%), breast (11.6% ). Up to 80% of detected malignant lung tumors are non-small cell carcinoma (NSCLC). Among patients with NSCLC, stage IIIB-IV of the process is diagnosed in 70% of cases. The median survival of patients in this group is 4-5 months, and only 10% of them survive 1 year from the moment of diagnosis. This study explored the most advanced clinical developments in the treatment of metastatic NSCLC discussed at the ASCO Annual Congress – 2022: new treatment options for mNSCLC with KRAS mutations and other targeted therapy strategies for mNSCLC.
The reviewed clinical developments on targeted combination therapy for metastatic NSCLC show promising results and an acceptable drug safety profile for its personalized administration to patients after progression under standard treatment conditions. Presented at ASCO – 2022, the results of clinical trials of the latest drug molecules indicate their serious antitumor efficacy. Personalized methods of selective suppression of specific effector pathways of oncogenesis have certain clinical advantages.
Keywords: metastatic non-small cell lung cancer, clinical trials, targeted therapy, KRAS, MET, EGFR
For citation: Zavyalov AA, Andreev DA, Varlamova SE. Clinical trials of metastatic non-small cell lung cancer therapy show promising results: ASCO Congress 2022. A.I. Burnasyan Federal Medical Biophysical Center Clinical Bulletin. 2022.3:41-47. (In Russian) DOI: 10.33266/2782-6430-2022-3-41-47
REFERENCES
1. Zugazagoitia J., Molina-Pinelo S., Lopez-Rios F., Paz-Ares L. Biological Therapies in Nonsmall Cell Lung Cancer. Eur. Respir. J. 2017;49;3:1601520. http://erj.ersjournals.com/lookup/doi/10.1183/13993003.01520-2016.
2. Zhang Y., Ren J.S., Huang H.Y., Shi J.F., Li N., Zhang Y., Dai M. International Trends in Lung Cancer Incidence from 1973 to 2007. Cancer Med. 2018;7;4:1479–1489.
3. Slugin Ye.N., Levchenko Ye.V., Imyanitov Ye.N., Lopushanskaya O.O. The Role of Egfr Mutation Testing in the Choice for Surgical Tactics in Nsclc Treatment. Voprosy Onkologii = Problems in Oncology. 2021;67;3:315–322 (In Russ.).
4. Zlokachestvennyye Novoobrazovaniya v Rossii v 2019 Godu (Zabolevayemost i Smertnost) = Malignant Neoplasms in Russia in 2019 (Morbidity and Mortality). Ed. Kaprin A.D., Starinskiy V.V., Shakhzadova A.O. Moscow Publ., 2020. 252 p. (In Russ.).
5. Andreyev D.A., Zavyalov A.A., Polyakova K.I., Davydovskaya M.V. Tyrosine Kinase Inhibitors in the Treatment of Advanced Lung Cancer from Example of Preferential Medicine Provision in Moscow City. Pulmonologiya = Russian Pulmonology Journal. 2020;30;4:463–472 (In Russ.).
6. Longkanker Nederland. IKNL. Cijfers over longkanker. URL: https://www.longkankernederland.nl/longkanker/statistieken (Accessed 2021 Aug 20).
7. Wang Y., Hu G. fang, Wang Z. The Status of Immunosuppression in Patients with Stage IIIB or IV Non-Small-Cell Lung Cancer Correlates with the Clinical Characteristics and Response to Chemotherapy. Onco Targets Ther. 2017;10:3557–3566. doi: 10.2147/OTT.S136259. eCollection 2017.
8. Stilidi I.S., Gevorkyan T.G., Shpak A.G. Improvement of Indicators of Federal Project Fight Against Oncological Diseases. Vestnik Roszdravnadzora= Bulletin of Roszdravnadzor. 2021;1:46–53 (In Russ.).
10. Van den Heuvel M., Dumoulin D. Oncologiejournaal 2022. Longcarcinoom. MEDtalks. URL: https://www.medtalks.nl/asco2022-longcarcinoom (Accessed 27.07.2022).
11. Mirati Therapeutics, Cision US Inc. New Late-Breaking Data on Investigational Adagrasib Show Regression of Central Nervous System (CNS) Metastases in Patients with KRASG12C-mutated Non-Small Cell Lung Cancer (NSCLC) with Active, Untreated CNS Metastases. URL: https://www.prnewswire.com/news-releases/new-latebreaking-data-on-investigational-adagrasib-show-regression-ofcentral-nervous-system-cns-metastases-in-patients-with-krasg12cmutated-non-small-cell-lung-cancer-nsclc-with-active-untreated-cns-me tastases-3 (Accessed 27.07.2022).
12. National Library of Medicine. Phase 1/2 Study of MRTX849 in Patients With Cancer Having a KRAS G12C Mutation KRYSTAL-1. URL: https://clinicaltrials.gov/ct2/show/NCT03785249 (Accessed 25.07.2022).
13. Sabari J.K., Spira A.I., Heist R.S., Janne P.A., Pacheco J.M., Weiss J., Gadgeel S.M., Der-Torossian H., Velastegui K., Kheoh T., Christensen J.G., Negrao M.V. Activity of Adagrasib (MRTX849) in Patients with KRASG12C-Mutated NSCLC and Active, Untreated CNS Metastases in the KRYSTAL-1 Trial. J. Clin. Oncol. 2022;40;17. https://doi.org/10.1200/JCO.2022.40.17_suppl.LBA9009.
14. Spira A.I., Riely G.J., Gadgeel S.M., Heist R.S., Ou S.H.I., Pacheco J.M., Johnson M.L., Sabari J.K., Leventakos K., Yau E., Bazhenova L., Negrao M.V., Pennell N.A., Zhang J., Velastegui K., Christensen J.G., yan xiaohong, Anderes K.L., Chao R.C., Janne P.A. KRYSTAL-1: Activity and Safety of Adagrasib (MRTX849) in Patients with Advanced/Metastatic Non–Small Cell Lung Cancer (NSCLC) Harboring a KRASG12C Mutation. J. Clin. Oncol. 2022;40;16suppl:9002. https://doi.org/10.1200/JCO.2022.40.16_suppl.9002.
15. National Library of Medicine. Phase 3 Study of MRTX849 (Adagrasib) vs Docetaxel in Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation (KRYSTAL-12). URL: https://clinicaltrials.gov/ct2/show/NCT04685135. (Accessed 26.07.2022).
16. Nakajima E.C., Ren Y., Vallejo J.J., Akinboro O., Mishra-Kalyani P.S., Larkins E.A., Drezner N.L., Tang S., Pazdur R., Beaver J.A., Singh H. Outcomes of First-Line Immune Checkpoint Inhibitors with or Without Chemotherapy According to KRAS Mutational Status and PD-L1 Expression in Patients with Advanced NSCLC: FDA Pooled Analysis. J. Clin. Oncol. 2022;40;16suppl:9001. https://doi.org/10.1200/JCO.2022.40.16_suppl.9001.
17. National Library of Medicine. Study of Amivantamab, a Human Bispecific EGFR and cMet Antibody, in Participants With Advanced Non- Small Cell Lung Cancer (CHRYSALIS). URL: https://clinicaltrials.gov/ct2/show/NCT02609776 (Accessed 26.07.2022).
18. Krebs M., Spira A.I., Cho B.C., Besse B., Goldman J.W., Janne P.A., Ma Z., Mansfield A.S., Minchom A.R., Ou S.H.I., Salgia R., Wang Z., Llacer Perez C., Gao G., Curtin J.C., Roshak A., Schnepp R.W., Thayu M., Knoblauch R., Lee C.K. Amivantamab in Patients with NSCLC with MET Exon 14 Skipping Mutation: Updated Results from the CHRYSALIS Study. J. Clin. Oncol. 2022;40;16suppl:9008. https://doi.org/10.1200/JCO.2022.40.16_suppl.9008.
19. Shu C.A., Goto K., Ohe Y., Besse B., Park K., Wang Y., Griesinger F.,Yang J.H., Felip E., Sanborn R.E., Caro R.B., Bauml J.M., Chen J., Fennema E., Mahoney J., Trani L., Knoblauch R.E., Thayu M., Cho B.C. 1193MO Amivantamab Plus Lazertinib in Post-Osimertinib, Post- Platinum Chemotherapy EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC): Preliminary Results from CHRYSALIS-2. Ann. Oncol. 2021;32:S952–953. https://linkinghub.elsevier.com/retrieve/pii/S092375342104028X.
20. National Library of Medicine. A Study of Lazertinib as Monotherapy or in Combination With Amivantamab in Participants With Advanced Non-small Cell Lung Cancer. URL: https://clinicaltrials.gov/ct2/show/NCT04077463 (Accessed 26.07.2022).
21. Shu C.A., Goto K., Ohe Y., Besse B., Lee S.H., Wang Y., Griesinger F., Yang J.C.H., Felip E., Sanborn R.E., Bernabe Caro R., Curtin J.C., Chen J., Mahoney J.M., Trani L., Bauml J.M., Knoblauch R.E., Thayu M., Cho B.C. Amivantamab and Lazertinib in Patients with EGFRMutant Non–Small Cell Lung (NSCLC) after Progression on Osimertinib and Platinum-Based Chemotherapy: Updated Results from CHRYSALIS-2. J. Clin. Oncol. 2022;40;16suppl:9006. https://doi.org/10.1200/JCO.2022.40.16_suppl.9006.
22. Tsimberidou A.M., Fountzilas E., Nikanjam M., Kurzrock R. Review of Precision Cancer Medicine: Evolution of the Treatment Paradigm. Cancer Treat. Rev. 2020;86:102019. https://linkinghub.elsevier.com/retrieve/pii/S0305737220300578.
23. National Cancer Institute. Tumor-Agnostic Therapy. URL: https://www.cancer.gov/publications/dictionaries/cancer-terms/def/tumor- agnostic-therapy (Accessed 27.07.2022).
24. Orlov-Slavu M.C., Popa A.M., Tulin A., Pantea Stoian A., Poiana C., Paleru C., Calu V., Nitipir C. The Utility of Next-Generation Sequencing in the Treatment Decision-Making for Metastatic Non-Small-Cell Lung Cancer. Cureus. 2021;13;8:e16919.
Conflict of interest. The authors declare no conflict of interest.
Financing. The study had no sponsorship.
Contribution. Article was prepared with equal participation of the authors.
Article received: 01.08.2022. Accepted for publication: 28.08.2022